⚠ Evidence warning: Clinical trials or other evidence do not support the claim that pandan tea lowers blood sugar or treats diabetes. This page keeps it as a report of what people, websites or other media say.

Pandan: Blood Sugar and Metabolic Claims Examined

“Pandan tea for diabetes” is by a wide margin the most-searched thing about this plant. It is also the least supported. That combination — heavy demand, thin evidence — is exactly the situation in which health writing tends to go wrong, so this page is deliberately structured around what the studies actually did rather than what they are said to have shown.

The short version, stated plainly up front: the pandan blood-sugar literature consists of test-tube enzyme assays, cell-culture work, rodent experiments, and one small human study whose glucose result went the wrong way. There has never been a randomised controlled trial of pandan in people with diabetes or prediabetes. There is no established dose, no known duration of effect, no data on drug interactions, and no evidence that drinking pandan tea changes anyone's hemoglobin A1c (HbA1c). No study has tested pandan tea as a treatment for diabetes or as a replacement for prescribed medication.

None of this is a finding against pandan as food: it is an aromatic leaf with a long culinary record. The gap is in the evidence for blood-sugar claims, and above all for capsules sold on them.

Table of Contents

  1. Where the Claim Comes From
  2. A Species and Plant-Part Problem First
  3. The 1998 Rat Study, Read Carefully
  4. The Only Human Study — and Its Surprise
  5. Alpha-Glucosidase and Alpha-Amylase Inhibition
  6. Why In-Vitro Enzyme Inhibition Rarely Survives Contact With a Human
  7. The Wider Rodent and Cell Literature
  8. What a Convincing Study Would Look Like
  9. The Real Risk: Interaction and Substitution
  10. How Pandan Tea Is Usually Made, and What Is Unstudied
  11. What Actually Moves Blood Sugar
  12. Evidence Tiers for This Page
  13. Key Research Papers
  14. Connections
  15. Featured Videos

Where the Claim Comes From

The pandan-for-diabetes idea has three separate roots, and they get tangled together in most retellings.

1. A genuine traditional thread — but a narrow one. In Thai household medicine, the root of the pandan plant has a small traditional reputation as a diuretic and for “heat” conditions including diabetes. Note the part: the best-documented use is the root. Traditional Malay and Vietnamese use of the leaf is mostly as a pleasant cooling drink and a kitchen aromatic, although the 2015 leaf study opens by stating that pandan leaves “are used in traditional medicine for the treatment of diabetes”. Leaf use for blood sugar is reported in traditional medicine, but it is less documented than the root use.

2. One purified compound in normal rats. A 1998 Thai paper isolated a hypoglycaemic constituent from pandan root and showed it lowered glucose in healthy rats. This is the single most-cited primary source in the whole edifice, and it is discussed in detail below.

3. Laboratory enzyme assays. Pandan leaf extracts inhibit alpha-glucosidase — and in some reports alpha-amylase — in the test tube. This is a real, reproducible in-vitro observation, and it is the mechanism most often quoted. It is also the finding most often overstated, because in-vitro enzyme inhibition is one of the easiest results to obtain from almost any plant extract and one of the hardest to translate into a person.

Stack those three and you get a story that sounds well-founded. Look at each one and the picture changes considerably.

A Species and Plant-Part Problem First

Before any result can be interpreted, two questions have to be answered about it: which plant? and which part? In the pandan literature these are not pedantic questions — they are the difference between studies.

And the parts: leaf, root, and fruit are not interchangeable. The best-known hypoglycaemic finding in the genus came from a root extract. Nobody drinks pandan root tea. The tea bags, the bundles at the market and the leaf juice in a chiffon cake are all leaf.

Throughout this page, the species and part used are stated for every study described. If a health article about pandan does not tell you which species and which part a study used, it has not read the study.

The 1998 Rat Study, Read Carefully

The foundational pharmacology paper is Peungvicha and colleagues, “4-Hydroxybenzoic acid: a hypoglycemic constituent of aqueous extract of Pandanus odorus root,” published in the Journal of Ethnopharmacology in 1998. A group at Mahidol University in Bangkok used activity-guided fractionation — splitting an extract, testing each fraction, following the activity — and arrived at 4-hydroxybenzoic acid as the compound responsible. Given orally at 5 mg/kg, it lowered blood glucose and raised serum insulin and liver glycogen.

That is a competent, honest piece of pharmacology. It is also nearly the opposite of what people cite it for. Four things to notice:

  1. The plant part was the root. Not the leaf. The root is not what anyone consumes.
  2. The agent was a single purified compound. Not a tea, not a leaf infusion, not a whole extract. Activity-guided fractionation exists precisely because whole extracts are usually too weak or too messy to be informative.
  3. The animals were normal rats, not diabetic ones. A glucose-lowering effect in a healthy animal tells you a compound is pharmacologically active; it does not tell you it helps a disease of insulin resistance. Many things lower glucose in a normal rat. The same group’s 1996 paper did test a whole water extract of the root in diabetic rats, with a glucose-lowering result (see the wider rodent literature) — still root, still rats.
  4. 4-hydroxybenzoic acid is not distinctive to pandan. It is a widely distributed simple phenolic acid found across the plant kingdom, including in many ordinary foods. If its presence made a plant antidiabetic, an enormous number of plants would be.

Evidence tier: preliminary (animal, purified compound, non-diabetic model, wrong plant part). This study is a legitimate starting point for research. It is not evidence that pandan-leaf tea lowers blood sugar in a person, and it has never been followed by the human work that would be needed to make it one.

The Only Human Study — and Its Surprise

There is one published human experiment, and its result is the part almost never reported: Chiabchalard and Nooron, “Antihyperglycemic effects of Pandanus amaryllifolius Roxb. leaf extract,” published in Pharmacognosy Magazine in 2015.

The human arm was small and simple. Thirty healthy volunteers received either pandan-leaf tea or hot water fifteen minutes after a standard 75 g oral glucose load — the same sugar challenge used in a glucose tolerance test. The paper's own reported outcome was that mean blood glucose was higher in the pandan group (6.16 ± 0.79 mmol/L) than in the hot-water control group (5.55 ± 0.98 mmol/L), a difference the authors described as statistically significant (P < 0.001). The abstract describes the leaf extracts for the laboratory arms (dried leaf in distilled water at 90°C for 15 minutes, or in 95% ethanol); it does not state how the volunteers’ tea was prepared.

Read that again, because it is the single most important sentence on this page. In the only human data that exists, pandan tea did not lower post-glucose blood sugar — the pandan group's readings were higher than the control group's. The paper's positive findings came entirely from its laboratory arms: the leaf extracts inhibited alpha-glucosidase, and increased insulin release from RINm5F rat insulinoma cells in a dose-dependent manner.

How should a small result like that be weighted? Cautiously, in both directions. Thirty healthy volunteers is a small sample; a single unreplicated finding in either direction is weak evidence; the participants were not diabetic; the tea's strength and 2AP content were not the sort of standardised variable a drug trial would control. It would be as wrong to declare that pandan raises blood sugar as it is to declare that it lowers it. But the honest reading is unavoidable: the one time anyone tested the actual claim in actual humans, the claim did not replicate. A field with a positive-results bias produced a negative human result, and that deserves more attention than it gets.

The 2024 Fitoterapia review of the plant by Wang and colleagues — the most comprehensive modern survey, cataloguing more than a hundred compounds — likewise describes the hypoglycaemic evidence as pharmacological, meaning preclinical. It does not report clinical trial evidence, because there is none to report.

Alpha-Glucosidase and Alpha-Amylase Inhibition

The mechanism offered for pandan is inhibition of the intestinal carbohydrate-digesting enzymes. It is worth understanding properly, because the mechanism is real even though the clinical claim is not established.

What these enzymes do. Alpha-amylase, from saliva and pancreas, breaks starch into shorter chains. Alpha-glucosidase, on the brush border of the small intestine, chops those into absorbable single sugars. Slow either one and glucose enters the bloodstream more gradually, blunting the post-meal spike.

This is a validated drug target. Acarbose, miglitol and voglibose are prescription alpha-glucosidase inhibitors used clinically, mainly for post-meal glucose control. Acarbose has real trial evidence behind it and real, well-known side effects — flatulence, bloating and diarrhoea, caused directly by undigested carbohydrate reaching the colon and being fermented there. Those side effects are a useful diagnostic, as the next section explains.

What pandan extracts do in a test tube. They inhibit alpha-glucosidase. This has been reported in the 2015 Pharmacognosy Magazine work and appears in the broader screening literature on Southeast Asian plants. Reports on alpha-amylase are less consistent. The inhibition is generally modest by the standards of these assays and is attributed to the leaf's ordinary phenolic content — catechin, epicatechin, rutin, kaempferol, naringin and the phenolic acids quantified in the 2013 Malaysian profiling study by Ghasemzadeh and Jaafar.

Evidence tier: preliminary (in vitro). Solid as an observation about enzymes in a cuvette. Not evidence about a person.

Why In-Vitro Enzyme Inhibition Rarely Survives Contact With a Human

This section is the crux of the whole page, and it generalises far beyond pandan — the same reasoning applies to cinnamon, to countless “blood-sugar support” botanicals, and to most plant-extract enzyme-inhibition claims you will encounter.

Concentration. An in-vitro assay applies a concentrated extract directly to purified enzyme. In a person, a cup of tea is diluted into the gut's contents, and the polyphenols responsible are present at a small fraction of the assay concentration. Plant polyphenols also bind indiscriminately to proteins in general — which is a well-known source of false-positive enzyme inhibition in these assays.

Site of action. Alpha-glucosidase sits on the intestinal brush border, downstream of the stomach. An inhibitor has to survive gastric acid, arrive at the right place at the right time relative to the meal, and be present at a sufficient local concentration. The 2015 study gave the tea fifteen minutes after the glucose load. Timing is not a detail here; it is most of the pharmacology.

Bioavailability and metabolism. Tea polyphenols are extensively metabolised by gut bacteria and by the liver. What reaches a target is often not the molecule that was tested.

And the diagnostic tell. Effective alpha-glucosidase inhibition has a characteristic, unmistakable consequence: undigested carbohydrate reaches the colon and ferments, producing gas, bloating and loose stools. That is why acarbose is poorly tolerated by many people. Nobody reports this from pandan tea. Hundreds of millions of people drink pandan-flavoured drinks and eat pandan-scented rice without any such effect. If pandan were meaningfully inhibiting intestinal carbohydrate digestion at culinary or tea-strength doses, the population would already know — the side effect is that noticeable. The absence of that signal is, in its own way, evidence.

The Wider Rodent and Cell Literature

Beyond the two studies above there is a scattered body of preclinical work on pandan and metabolic endpoints, mostly from Southeast Asian groups, and it is worth describing as a body rather than paper by paper — which is itself the honest characterisation.

The methodological problem running through all of it is extract heterogeneity. As covered on the aroma chemistry page, fresh leaf, dried leaf, aqueous juice, ethanol extract and essential oil are chemically different materials. There is no accepted standardisation marker for pandan — no equivalent of the curcuminoid percentage on a turmeric label. Two studies both reporting on “pandan leaf extract” may have used preparations with little in common. That alone makes pooling the literature impossible.

What a Convincing Study Would Look Like

It is more useful to say precisely what is absent than to gesture at “more research is needed.” For pandan and blood sugar, the missing items are:

  1. A randomised, placebo-controlled trial in people with type 2 diabetes or prediabetes. Not healthy volunteers. Zero such trials exist.
  2. A defined, standardised preparation. Stated species, plant part, extraction method, and quantified marker compound, so the study could be replicated and a product could be matched to it.
  3. A dose-finding study. There is currently no established medicinal dose of pandan for anything. Any number on a supplement label is invented rather than derived.
  4. Meaningful endpoints over a meaningful duration. Hemoglobin A1c over three months, or continuous glucose monitoring across real meals — not a single reading after a sugar drink.
  5. Human pharmacokinetics. Nobody knows what pandan's constituents do in a human body: absorption, distribution, metabolism, elimination. This is completely unstudied.
  6. Formal interaction studies with metformin, sulfonylureas, insulin and sodium-glucose cotransporter-2 (SGLT2) inhibitors. None exist.
  7. Toxicology for concentrated extracts. Very little exists, which is why the safety page treats capsules quite differently from cooking.

Until at least the first three exist, the correct label for pandan and blood sugar is UNKNOWN, not “promising.” “Promising” is what a supplement marketer says about an absence of evidence.

The Real Risk: Interaction and Substitution

Pandan leaf in food is not dangerous. The risk here is not toxicity; the different risks are set out one by one below.

Risk 1 — substitution. This is the serious one. Someone with type 2 diabetes reads that pandan tea is a natural blood-sugar remedy, feels reassured, and lets a prescription lapse or skips glucose monitoring. Uncontrolled hyperglycaemia damages kidneys, retinas, nerves and blood vessels quietly over years. A pleasant tea with no demonstrated glucose-lowering effect cannot do the work of metformin, insulin, dietary change or clinical follow-up. If pandan tea makes a person feel their diabetes is handled, it has caused harm without any pharmacological action at all.

Risk 2 — additive hypoglycaemia, theoretical but worth respecting. Suppose pandan does have a modest glucose-lowering action that the single small human study missed. Someone on insulin or a sulfonylurea — drugs that can cause hypoglycaemia on their own — who starts drinking strong pandan decoctions several times a day has added an unquantified variable. There are no interaction studies, so any added effect on top of these drugs is unmeasured.

Risk 3 — concentrated extracts and capsules. The exposure that has never been studied. Pandan's long culinary safety record supports culinary amounts of leaf. It says nothing about a standardised extract in a capsule taken daily, and pandan's poorly characterised alkaloids — pandamarilactones and relatives — are the concrete reason the two are not equivalent. Marketed pandan blood-sugar supplements have no human trial behind them, no standardisation, and no toxicology.

Risk 4 — the sugar the pandan arrives with. Worth stating because it is the most common real-world metabolic effect of pandan consumption. Pandan chiffon cake, kaya, sweetened pandan drinks, pandan bubble tea and pandan condensed-milk desserts are sugar-delivery vehicles. Someone managing blood sugar who increases pandan intake through the dessert route has made their glycaemic control worse, not better, whatever the leaf does. The savoury pot is the better route: a knotted leaf in brown rice, congee, curry or coconut-milk vegetables adds aroma and nothing else.

How Pandan Tea Is Usually Made, and What Is Unstudied

Pandan tea is a pleasant, aromatic, calorie-free hot drink with a long record of casual use.

What Actually Moves Blood Sugar

Since people arrive at pages like this one looking for help with real glucose problems, it would be evasive to critique pandan and stop. The interventions with genuine human trial evidence behind them are not mysterious, and none of them is a tea:

Pandan can sit alongside all of that as a flavouring. It cannot substitute for any of it.

Evidence Tiers for This Page

Key Research Papers

Named papers link to their PubMed records; the remaining links are PubMed topic searches, which return current literature rather than a single fixed record. Note the Pandanus odorus synonym — searching only the current name misses the foundational pharmacology.

  1. Chiabchalard A and Nooron N (2015). “Antihyperglycemic effects of Pandanus amaryllifolius Roxb. leaf extract,” Pharmacognosy Magazine. The only human data: 30 healthy volunteers, 75 g glucose load, pandan tea versus hot water — and post-load glucose higher in the pandan group. Positive findings were in vitro. 11(41):117–22 — PubMed PMID: 25709220
  2. Peungvicha P and colleagues (1998). “4-Hydroxybenzoic acid: a hypoglycemic constituent of aqueous extract of Pandanus odorus root,” Journal of Ethnopharmacology. Purified compound, 5 mg/kg orally, normal rats, root not leaf. 62(1):79–84 — PubMed PMID: 9720616
  3. Peungvicha P, Thirawarapan SS, Watanabe H (1996). “Hypoglycemic effect of water extract of the root of Pandanus odorus RIDL.,” Biological and Pharmaceutical Bulletin. Root water extract in normal and streptozotocin-diabetic rats. 19(3):364–366 — PubMed PMID: 8924901
  4. Wang W and colleagues (2024). “Botany, phytochemistry, pharmacology, and applications of Pandanus amaryllifolius Roxb.: a review,” Fitoterapia. The comprehensive modern survey; describes the hypoglycaemic evidence as pharmacological (preclinical), and reports no clinical trials. 177:106144 — PubMed PMID: 39053743
  5. Ghasemzadeh A and Jaafar HZE (2013). “Profiling of phenolic compounds and their antioxidant and anticancer activities in pandan (Pandanus amaryllifolius Roxb.) extracts from different locations of Malaysia,” BMC Complementary and Alternative Medicine. Quantifies the catechin, epicatechin, naringin, rutin and kaempferol content — the phenolic compounds other papers credit with the enzyme inhibition — and tests antioxidant and anticancer (MCF-7 cell) activity, showing how much they vary by growing site; it did not test enzyme inhibition. 13:341 — PubMed PMID: 24289290
  6. Reshidan NH, Abd Muid S, Mamikutty N (2019). “The effects of Pandanus amaryllifolius (Roxb.) leaf water extracts on fructose-induced metabolic syndrome rat model,” BMC Complementary and Alternative Medicine. Rat study. 19(1):232 — PubMed PMID: 31462242
  7. Kerdsuknirund S, Kupittayanant P, Tongdee P, Nimkuntod P, Kupittayanant S (2026). “Pandanus amaryllifolius and Tectona grandis Extracts Improve Fetal Outcomes in Streptozotocin-Induced Gestational Diabetes in Rats,” International Journal of Molecular Sciences. Two-herb formula, rats. 27(2):857 — PubMed PMID: 41596503
  8. The pandan diabetes literature as a whole. Small enough that a single search returns essentially all of it — which is itself the finding. Search: Pandanus amaryllifolius and diabetes
  9. Pandan and alpha-glucosidase inhibition. The in-vitro mechanism, in context alongside the wider screening literature on Southeast Asian plants. Search: Pandanus amaryllifolius alpha-glucosidase inhibition
  10. Plant extracts, alpha-glucosidase inhibition and postprandial glucose in humans. The general question of whether in-vitro enzyme inhibition by botanicals translates — the essential context for reading any such claim. Search: botanical alpha-glucosidase inhibitors and postprandial glucose trials. — Search PubMed
  11. Acarbose and the alpha-glucosidase inhibitor drug class. What validated inhibition looks like clinically, including the gastrointestinal side effects that pandan conspicuously does not produce. Search: acarbose in type 2 diabetes
  12. 4-hydroxybenzoic acid across the plant kingdom. Context for why the presence of this simple phenolic acid is not distinctive to pandan. Search: 4-hydroxybenzoic acid distribution and metabolism
  13. Herbal supplements and diabetes medication interactions. The general safety literature that ought to exist for pandan and does not. Search: herb–drug interactions with antidiabetic medication. — Search PubMed
  14. Cinnamon for glycaemic control. The closest well-studied parallel — a kitchen spice with a widely marketed blood-sugar claim, tested repeatedly in humans with inconsistent and generally small results. Useful for calibrating expectations about pandan. Search: cinnamon and glycaemic control meta-analyses
  15. Pandanus tectorius — a different species entirely. Frequently and wrongly cited as pandan-leaf evidence. Search: Pandanus tectorius fruit

External Resources

  1. PubMed — the database behind the search links above.
  2. NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases) — US government reference on diabetes management.
  3. NCCIH (National Center for Complementary and Integrative Health) — evidence summaries on herbs and supplements.
  4. American Diabetes Association — patient-facing standards of care.
  5. Diabetes UK — patient information and evidence reviews.

Connections


Safety note and disclaimer. Pandan leaf as a culinary flavouring has a long record of ordinary safe use; that record does not extend to concentrated extracts or supplements, which have no human safety or efficacy data. No study has tested pandan as a treatment for diabetes or prediabetes, or as a replacement for prescribed medication, dietary change or glucose monitoring. Insulin and sulfonylureas can cause hypoglycaemia on their own, and no study has measured what regular strong pandan preparations add to them. Concentrated pandan extracts are unstudied in pregnancy and breastfeeding. This article is general information for education, not medical advice, and it is not a substitute for individual assessment by a qualified clinician.

Back to Table of Contents